NRX Pharmaceuticals, Inc. (NRXP) stock
NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.80+0.35 (+14.29%)
Close on Nov 18, 2026Market cap $121.23MP/E –Yield –
NRX Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
NRX Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$19.90M. For fiscal 2025 it was -$16.22M. The highest annual figure on record is -$713.19K in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$16.22M | – |
| FY2024 | Dec 31, 2024 | -$18.50M | – |
| FY2023 | Dec 31, 2023 | -$27.84M | – |
| FY2022 | Dec 31, 2022 | -$44.34M | – |
| FY2021 | Dec 31, 2021 | -$115.80M | – |
| FY2020 | Dec 31, 2020 | -$51.39M | – |
| FY2019 | Dec 31, 2019 | -$713.19K | – |
| FY2018 | Dec 31, 2018 | -$1.01M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.51M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.74M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.62M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.02M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.73M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.85M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.43M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.02M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.05M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.00M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.41M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.81M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.19M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.85M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.89M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.14M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.60M | – |
| Q1 FY2022 | Mar 31, 2022 | -$15.71M | – |
| Q4 FY2021 | Dec 31, 2021 | -$52.98M | – |
| Q3 FY2021 | Sep 30, 2021 | -$20.10M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.12M | -16430.1% |
| Q1 FY2021 | Mar 31, 2021 | -$25.61M | – |
| Q4 FY2020 | Dec 31, 2020 | -$45.12M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.15M | – |
| Q2 FY2020 | Jun 30, 2020 | $104.82K | – |
| Q1 FY2020 | Mar 31, 2020 | -$119.30K | – |
| Q4 FY2019 | Dec 31, 2019 | -$190.96K | – |
| Q3 FY2019 | Sep 30, 2019 | -$183.31K | – |
| Q2 FY2019 | Jun 30, 2019 | -$175.74K | – |
| Q1 FY2019 | Mar 31, 2019 | -$163.18K | – |
| Q4 FY2018 | Dec 31, 2018 | -$322.08K | – |
| Q3 FY2018 | Sep 30, 2018 | -$220.24K | – |
| Q2 FY2018 | Jun 30, 2018 | -$271.81K | – |
| Q1 FY2018 | Mar 31, 2018 | -$192.37K | – |
| Q4 FY2017 | Dec 31, 2017 | -$134.48K | – |
See a number that looks wrong?